598 related articles for article (PubMed ID: 28494631)
21. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
22. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
23. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
24. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
25. Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG; Ribatti D; Vacca A; Einsele H
Leuk Res; 2016 Mar; 42():93-104. PubMed ID: 26818572
[TBL] [Abstract][Full Text] [Related]
26. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
27. Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.
Shah H; Stephens D; Seymour J; Maddocks K
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-18. PubMed ID: 33770460
[TBL] [Abstract][Full Text] [Related]
28. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
29. Composite lymphoma and related disorders.
Kim H
Am J Clin Pathol; 1993 Apr; 99(4):445-51. PubMed ID: 8475911
[TBL] [Abstract][Full Text] [Related]
30. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
Karlin L; Coiffier B
Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
[TBL] [Abstract][Full Text] [Related]
31. Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas.
Sekikawa T; Takahara S; Suzuki H; Takeda N; Yamada H; Horiguchi-Yamada J
Eur J Haematol; 2007 Mar; 78(3):264-9. PubMed ID: 17253969
[TBL] [Abstract][Full Text] [Related]
32. Richter syndrome in B-cell chronic lymphocytic leukemia.
Nakamura N; Abe M
Pathol Int; 2003 Apr; 53(4):195-203. PubMed ID: 12675762
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes.
Shimizu S; Tamagawa Y; Kojima H; Mori N; Nagata M; Noguchi M; Nagasawa T
Eur J Haematol; 2003 Feb; 70(2):119-24. PubMed ID: 12581194
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.
Barth TF; Barth CA; Kestler HA; Michl P; Weniger MA; Buchholz M; Möller P; Gress T
J Pathol; 2007 Feb; 211(3):305-13. PubMed ID: 17152084
[TBL] [Abstract][Full Text] [Related]
38. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
Klein C; Jamois C; Nielsen T
Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
[TBL] [Abstract][Full Text] [Related]
40. Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Zhuang Y; Xu W; Shen Y; Li J
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):347-52. PubMed ID: 21030347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
